Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis

Madeleine Durand, Mireille E Schnitzer, Menglan Pang, Greg Carney, Sherif Eltonsy, Kristian B Filion, Anat Fisher, Min Jun, I Fan Kuo, Alexis Matteau, J Michael Paterson, Jacqueline Quail, Christel Renoux, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, Madeleine Durand, Mireille E Schnitzer, Menglan Pang, Greg Carney, Sherif Eltonsy, Kristian B Filion, Anat Fisher, Min Jun, I Fan Kuo, Alexis Matteau, J Michael Paterson, Jacqueline Quail, Christel Renoux, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators

Abstract

Aims: There are conflicting signals in the literature about comparative safety and effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF).

Methods: We conducted multicentre matched cohort studies with secondary meta-analysis to assess safety and effectiveness of dabigatran, rivaroxaban and apixaban across 9 administrative healthcare databases. We included adults with NVAF initiating anticoagulation therapy (dabigatran, rivaroxaban or apixaban), and constructed 3 cohorts to compare DOACs pairwise. The primary outcome was pooled hazard ratio (pHR) of ischaemic stroke or systemic thromboembolism. Secondary outcomes included pHR of major bleeding, and a composite of stroke, major bleeding, or all-cause mortality. We used proportional hazard Cox regressions models, and pooled estimates were obtained with random effect meta-analyses.

Results: The cohorts included 73 414 new users of dabigatran, 92 881 of rivaroxaban, and 61 284 of apixaban. After matching, the pHRs (95% confidence intervals) comparing rivaroxaban initiation to dabigatran were: 1.11 (0.93, 1.32) for ischaemic stroke or systemic thromboembolism, 1.26 (1.09, 1.46) for major bleeding, and 1.17 (1.05, 1.30) for the composite endpoint. For apixaban vs dabigatran, they were: 0.91 (0.74, 1.12) for ischaemic stroke or systemic thromboembolism, 0.89 (0.75, 1.05) for major bleeding, and 0.94 (0.78 to 1.14) for the composite endpoint. For apixaban vs rivaroxaban, they were: 0.85 (0.74, 0.99) for ischaemic stroke or systemic thromboembolism, 0.61 (0.53, 0.70) for major bleeding, and 0.82 (0.76, 0.88) for the composite endpoint.

Conclusion: We found that apixaban use is associated with lower risks of stroke and bleeding compared with rivaroxaban, and similar risks compared with dabigatran.

Keywords: atrial fibrillation; direct oral anticoagulants; epidemiology; stroke.

© 2020 British Pharmacological Society.

References

REFERENCES

    1. Heart and Stroke Foundation. Atrial Fibrillation - Be pulse aware 2014 [Available from:
    1. Verma A, Cairns JA, Mitchell LB, et al. focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114-1130.
    1. National Institute for health and Care Excellence. Atrial Fibrillation: the management of atrial fibrillation. June 2014: Natational Clinical Guidelines Center; 2014. p. 1-420.
    1. January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J am Coll Cardiol. 2014;64(21):e1-e76.
    1. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125-136.
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
    1. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
    1. Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017;23(9):968-978.
    1. Deitelzweig S, Keshishian A, Li X, et al. Comparison Of Effectiveness, Safety, And The Net Clinical Outcome Between Different Direct Oral Anticoagulants In 162,707 Non-Valvular Atrial Fibrillation Patients Treated In US Clinical Practice. J am Coll Cardiol. 2018;71(11, Supplement):A275.
    1. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016;176(11):1662-1671.
    1. Gupta K, Trocio J, Keshishian A, et al. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. J Manag Care Spec Pharm. 2018;24(11):1116-1127.
    1. Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(5):975-986.
    1. Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85(2):422-431.
    1. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest. 2016;150(6):1302-1312.
    1. Tepper PG, Mardekian J, Masseria C, et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLOS ONE. 2018;13(11):e0205989.
    1. Villines TC, Ahmad A, Petrini M, et al. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system. European Heart Journal - Cardiovascular Pharmacotherapy. 2019;5(2):80-90.
    1. Graham DJ, Baro E, Zhang R, et al. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Am J Med. 2019;132(5):596-604.e11.
    1. Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-2944.
    1. Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med Peer-Reviewed, Independent, Open-Access J. 2012;6(4):e134-e140.
    1. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386(9990):281-291.
    1. StataCorp. Stata Statistical Software. Release. 14 StataCorp LP: College Station TX; 2015.
    1. Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor. Curr Clin Pharmacol. 2014;9(1):75-83.
    1. Bayer Inc. Product Monograph Xarelto. 2015:1-75.
    1. Dempfle CE. Direct oral anticoagulants--pharmacology, drug interactions, and side effects. Semin Hematol. 2014;51(2):89-97.
    1. Boehringer Ingelheim Canada Ltd. Product Monograph Pradaxa. 2016:1-70.
    1. Pfizer Canada. Bristol-Myers Swuibb Canada. Product Monograph: Eliquis; 2016:1-77.
    1. Neild GH. Life expectancy with chronic kidney disease: an educational review. Pediatric Nephrol (Berlin, Germany). 2017;32(2):243-248.
    1. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
    1. Alexander SPH, Kelly E, Mathie A, et al. The Concise Guide To Pharmacology 2019/20: Introduction and Other Protein Targets. Br J Pharmacol. 2019;176(Suppl 1):S1-S20.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner